Related Experiment Video
Updated: Aug 9, 2026

Experimental Metastasis Assay
Published on: August 24, 2010
Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts
1Group of Radiation Biology and Tumor Physiology, Department of Biophysics, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo, Norway. e.k.rofstad@labmed.uio.no
Abstract:
Some cancer patients show accelerated growth of pre-existing metastases after removal of the primary tumor. The purpose of this study was to investigate whether primary tumor-induced metastasis suppression can be mediated by thrombospondin-1 in melanoma. Human melanoma xenografts (D-12, R-18, and U-25) were used as models of melanoma in humans. Melanoma angiogenesis, lung colonization, and spontaneous pulmonary metastasis were inhibited in mice bearing D-12, U-25, or thrombospondin-1 overexpressing R-18 tumors, which showed high thrombospondin-1 expression and secreted large quantities of thrombospondin-1 into the blood, but not in mice bearing wild-type R-18 tumors, which were negative for thrombospondin-1. D-12 tumors suppressed the growth of their own spontaneous metastases. The anti-angiogenic and anti-metastatic effects of D-12 and U-25 tumors were blocked in mice treated with thrombospondin-1 neutralizing antibody. Dormant avascular microcolonies having an elevated apoptotic activity were seen in the lungs of mice bearing D-12 or U-25 tumors, whereas only neovascularized lung macrocolonies were seen in control and antibody-treated mice. This study suggests that some melanoma patients may benefit from combined local treatment and long-term anti-angiogenic therapy involving thrombospondin-1.
Insights
Thrombospondin-1 may suppress melanoma metastasis by inhibiting angiogenesis and tumor growth. This suggests combining local treatments with thrombospondin-1-based therapies could benefit melanoma patients.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Primary tumor removal can sometimes accelerate metastasis growth in cancer patients.
- The role of thrombospondin-1 in primary tumor-induced metastasis suppression is not fully understood.
Purpose of the Study:
- To investigate if thrombospondin-1 mediates primary tumor-induced metastasis suppression in melanoma.
- To explore the potential of thrombospondin-1 in melanoma treatment strategies.
Main Methods:
- Utilized human melanoma xenografts (D-12, R-18, U-25) in mouse models.
- Assessed melanoma angiogenesis, lung colonization, and spontaneous pulmonary metastasis.
- Administered thrombospondin-1 neutralizing antibody to evaluate its effect on anti-angiogenic and anti-metastatic properties.
Main Results:
- Melanoma angiogenesis and metastasis were inhibited in mice with high thrombospondin-1 expressing tumors.
- Thrombospondin-1 neutralizing antibody blocked the anti-angiogenic and anti-metastatic effects.
- Dormant, avascular microcolonies with high apoptosis were observed in lungs of mice with thrombospondin-1 expressing tumors.
Conclusions:
- Thrombospondin-1 plays a significant role in suppressing melanoma metastasis.
- Combined local treatment and long-term anti-angiogenic therapy involving thrombospondin-1 may benefit melanoma patients.

